

SCRI Trials and Trial Regimen Updates

The following updates were completed between Feb. 20 - March 19, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
25061	USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Eribulin Q21D - v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Gemcitabine + Carboplatin Q21D - v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Nab-Paclitaxel Q28D - v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Paclitaxel Q21D - v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Paclitaxel Q28D - v2.0 15Aug2025
25087	USOR 25087 BRE 471 Phase 1b GDC-4198 + Giredestrant Q28D - v2.0 04JUN2025 USOR 25087 BRE 471 Phase 1b GDC-4198 Q28D - v2.0 04JUN2025 USOR 25087 BRE 471 Phase 2 GDC-4198 + Giredestrant Q28D - v2.0 04JUN2025 USOR 25087 BRE 471 Phase 2 Giredestrant + Abemaciclib Q28D - v2.0 04JUN2025
25137	USOR 25137 GYN 164 Phase 3 Bevacizumab maintenance Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Carboplatin + Pegylated Liposomal Doxorubicin + Bevacizumab Q28D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Gemcitabine + Carboplatin + Bevacizumab Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Gemcitabine Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 LY4170156 + Bevacizumab Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 LY4170156 Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Mirvetuximab Soravtansine Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Paclitaxel + Carboplatin + Bevacizumab Q21D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Paclitaxel Q28D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Pegylated Liposomal Doxorubicin Q28D - 31Oct2025 USOR 25137 GYN 164 Phase 3 Topotecan Q28D - 31Oct2025
25040	USOR 25040 LUN 619 Phase 2 Exploratory Arm V940 + Docetaxel Q21D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction Pembrolizumab + Nab-paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction Pembrolizumab + Paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction V940 or Placebo + Pembrolizumab + Nab-paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction V940 or Placebo + Pembrolizumab + Paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Maintenance V940 or Placebo + Pembrolizumab Q42D 11Jul2025

Study Number	Notes for New Build
25142	USOR 25142 GU 298 Phase 3 Safety Lead-In Vepugratinib + Enfortumab vedotin-ejfv + Pembrolizumab Q21D - 01Aug2025 USOR 25142 GU 298 Phase 3 Vepugratinib or Placebo + Enfortumab vedotin-ejfv + Pembrolizumab Q21D - 01Aug2025
25175	USOR 25175 GU 302 Phase 1b Cohort B Part 1 PF-08634404 + Enfortumab Vedotin Q21D - 26Jan2026 USOR 25175 GU 302 Phase 1b/2 Cohort A PF-08634404 Q21D - 26Jan2026
25065	USOR 25065 LUN 623 Phase 3 Atezolizumab Q21D - v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Durvalumab Q28D - v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Nivolumab Q28D - v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Pembrolizumab Q21D - v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Zongertinib Q42D (C1-10) - v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Zongertinib Q84D (C11-18) - v1.0 19JUN2025
25153	USOR 25153 LUN 644 Phase 3 Punitamig or Pembrolizumab Q21D - 09DEC2025
25152	USOR 25152 LUN 643 Phase 3 Durvalumab Q28D - 09Dec2025 USOR 25152 LUN 643 Phase 3 Punitamig Q21D - 09Dec2025

Updated Reference Information

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
22118	Amendment 3 16APR2025	Regimen Comments; Administration	Update drug; instructions
22322	PA Version J; 11th July 2025	N/A	Update drug; instructions
22332	Version 3.0; 21 July 2025	Regimen comments; admin	Update drug; instructions
23031	PA v6.0: 02 Dec 2025	Regimen comments; admin	Update drug; instructions, premedication, New Arms
23031	PM v6.0; 20th January 2026	N/A	Update Drug; instructions
23041	Version 8.0; 03 November 2025	Regimen Comments; prophylaxis	Update drug; instructions
23244	Protocol Amendment V 3.0, 04DEC2024, Clarification letter for protocol v2.0, Protocol amendment v2.0	N/A	Update drug; admin/prep

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
23245	PA 03: 04 Sep 2025	N/A	Update drug; instructions, procurement. Added drug
23292	Protocol v20.0; 12th November 2025	Regimen comments; admin	N/A
24005	PA v3.0: 13 Sept 2024	N/A	Update drug; admin/prep, Name
24021	PA v2.0; 25th June 2025	Regimen Comments; admin, premedication	Update drug; instructions, predmedication, frequency. Added drug
24110	PM v5.0; 9th February 2026	N/A	Update drug; instructions
24110	PM Pembrolizumab v3.0; 9-February-2026	N/A	Update Drug Instructions
24157	PM v4.0: 19 Nov 2025	N/A	Update drug; instructions
24168	Amendment 7.0/US-1, v1.0; 10 March 2025	Regimen comments; prophylaxis, observation	Update drug; instructions, premedication, dose/form
24170	PM v5.0; 04 November 2025	N/A	Update drug; dose/form
24170	Version 2.0; 04 November 2025	Regimen Comments; administration	Update drug; dose/form, instructions
24321	Version 1.0; 26 Sept 2025	Regimen comments; prophylaxis	Update drug; instructions, premedication
24325	PM v.3.0; 3rd February 2026	N/A	Update drug; procurement
24333	IP Procurement Update	N/A	Update drug; procurement
25049	PM v2.0; 2-March-2026	N/A	Update drug; instructions
23297	Memo; 27 August 2025	N/A	New Arms
24270	PM v6: 19 Dec 2025	N/A	Update Drug; admin/prep
24155	PM v5.0; 6th October 2025	N/A	Update drug; admin/prep

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
24203	PA01: 10 Sep 2025	Regimen Comments; administration, premedication	Update drug; instructions
24266	Protocol v2.0; 5-December-2025	Regimen Comments; premedication	New Arms. Update Drug; instructions
25031	Protocol v2.0; 5-December-2025	N/A	Update drug; admin/prep
24293	Procurement change	N/A	Update drug; procurement
22333	Version 7.0; 2nd February 2026	Regimen comments; administration	Update drug; instructions, premedication
RM 1276 MCCR	Version 4.0; 22nd December 2025	Regimen comments; prophylaxis	N/A
23284	PM v5.1: 17 Jul 2025	N/A	Update drug; instructions.